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Abstract
Background: As a result of successful PMTCT programs, children born from HIV-infected mothers are now
effectively protected from contracting the infection. However, it is not well known whether in utero exposure to the
virus and the subsequent exposure to Cotrimoxazole (CTX) prophylaxis affect the cell mediated immune system of
the children. This observational prospective study was aimed at determining how CD4+ T, CD8+ T and B cell
subsets varied in HIV-exposed but uninfected (HEU) children at different ages.
Methods: We recruited HEU and HIV-unexposed and uninfected (HUU) children from 6 months of age and
followed them up until they were 18 months old. HEU children received daily CTX prophylaxis beginning at
6 weeks of age until when 12 months of age. Venous blood samples were collected 6 monthly and analysed for
different subsets of CD8+ T, B cells and totalCD4+ T cells.
Results: At 6 months of age, HEU children had a lower percentage of total CD4+ T cells compared to HUU children
and a lower proportion of naïve CD8+ T cells but higher percentage of effector memory CD8+ T cells compared to
HUU children. HEU and HUU children had similar proportions of all B cell subsets at all ages.
Conclusions: The study showed that the subtle variations in CD4+ and CD8+ T cell subsets observed at 6 months
do not last beyond 12 months of age, suggesting that HEU children have a robust cell-mediated immune system
during first year of life.
Trial registration: This article report is not based on results of a controlled health-care intervention
Background
Lately the number of HIV-exposed but uninfected (HEU)
children (HIV negative children born from HIV-infected
mothers) has substantially increased due to the scaling up
of prevention of mother to child transmission (PMTCT)
programs [1]. Although HEU children are not infected with
the virus, some studies have still shown that the immune
system of these children might have long-term changes
either due to in utero exposure to HIV viral particles or
antiretroviral (ART) exposure [2]. These changes are
thought to have a negative effect on the response to infec-
tions as evidenced by the high morbidity in HEU children
early in life [3, 4]. However, most of these studies were
predominantly undertaken in HEU neonates and during
the era before the advent of daily Cotrimoxazole (CTX)
prophylaxis for HEU children and that of lifelong ART for
pregnant women and lactating mothers.
The adaptive immune system’s success in combating
infection relies heavily on putting up a robust response
and timely and appropriate differentiation of the B and T
lymphocytes into specific phenotypes. T helper (CD4+)
and T cytotoxic (CD8+) T cells are classified either as
naïve, effector or memory based on the immune function
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they perform [5]. Naïve T cells, characterized by the
expression of CD45RA+, continuously circulate between
the secondary lymphoid organs and blood via the lymph-
atic system [6] and recognize antigens during infection
[7]. The naïve T cells are then activated, expand and differ-
entiate into either short-lived effector T cells or memory
precursor effector T cells that survive for a longer period
and provide protection during re-infection with the same
pathogen [8]. Memory T cells are classified either as
effector memory (TEM) (CD45RA
−CCR7−) or central mem-
ory (TCM) T cells (CD45RA
−CCR7+) [9].
Depending on age, circulating human B cells in healthy
individuals comprise naïve (CD19+CD27−CD21hiCD10−),
and memory B cells that express either unswitched or
switched antibody isotypes [10–12]. A population of plasma
cells that represent the terminally differentiated mature
effector B cells and express CD19+CD27+CD38hiCD10− is
found in very low numbers [10, 13]. Protective humoral
immune response with optimal longevity depends on gen-
eration of memory B cells that are classified into classical
memory that are typically CD19+CD27+CD21hiCD10− and
activated memory expressing CD19+CD27+CD21loCD10−
[14]. Transitional immature B cells, a minor population of
circulating B cells, express an immature phenotype (CD19
+CD27−CD21loCD10+) and have reduced capacity to be
activated [10]. Recently a unique memory B cell sub-
population characterized by surface markers CD19+CD27
−CD21loCD10− and defined by the expression of the inhibi-
tory receptor Fc-receptor-like-4 (FCRL4) has been identi-
fied [15].
Currently little is known about the phenotypic changes
of B and T cell populations in peripheral blood of HEU
children in the era of lifelong ART in pregnancy and lac-
tating mothers and also in HEU children on CTX
prophylaxis during the first year of life. Although CTX
has been shown to prevent opportunistic bacterial infec-
tions in HIV-infected individuals [16–18] little is known
of its effect on the development of the immune system in
HEU children. Therefore, the aim of this study was to
characterize B and T cell phenotypic changes in HEU
Malawian children during and after completion of daily
Cotrimoxazole prophylaxis.
Methods
Study site, participants and design
Details of the study site and participants have already been
reported previously [19]. Briefly, we recruited HEU children
and HUU children from 6 months of age and followed
them up until they were 18 months old in Zomba, Malawi.
HEU children who had confirmed PCR negative results
were randomly selected from the ART clinic at the Zomba
central hospital. The children received daily CTX prophy-
laxis beginning at 6 weeks of age until at 12 months of age
where we conducted a rapid test to rule out HIV infection
and the mothers were asked to stop breastfeeding. The
children were eligible for inclusion if there were otherwise
healthy, breastfeeding, not under any medication and if
the mothers indicated their intention to reside in the
catchment area for the duration of the study. HUU chil-
dren were those that were HIV-uninfected and recruited
from HIV-uninfected mothers residing in the same area as
HEU children. Those who were severe malnourished,
anaemic, or who presented with other illnesses such as
malaria, diarrhea or influenza were excluded from the
study. In addition, only those who had not received any
malaria medication during the two months before recruit-
ment were included in the HUU group. Both HEU and
HUU children were seen every six months and at each
visit, 1 ml of venous blood was collected in EDTA tubes
for immunophenotyping to characterize the T and B cell
subsets.
Ethical approval
The study was reviewed and approved by the College of
Medicine Research Ethics Committee (COMREC) (P.05/
10/954). Individual written informed consent was obtained
from the parents or guardians of all the children who par-
ticipated in the study.
T and B cell characterisation
Whole blood samples were labelled with anti CD3 PE, anti
CD4 PerCP, anti CD8 APC-H7 (all from BD Biosciences,
San Jose, California), anti CD45RA FITC (BD Pharmingen,
San Jose, California) and anti CCR7 APC (eBiosciences,
San Diego, California). The following classification was
used for different cell types; T helper (CD3+CD4+) and T
cytotoxic (CD3+CD8+). The following additional criteria
was used for the different subsets; naïve (CD45RA+CCR7+),
central memory (CD45RA−CCR7+), effector memory
(CD45RA−CCR7−) and terminally differentiated effector
cells (CD45RA+CCR7−).
For the B cells, whole blood was labelled with anti
CD19 APC, anti CD21 PE-cy5 (all from BD Pharmin-
gen, San Jose, California), anti CD10 FITC and anti
CD27 PE (eBiosciences, San Diego, California). B
cells were identified as CD19+ and subpopulations of
naïve as CD19+CD27−CD21hiCD10−, classical memory
as CD19+CD27+CD21hiCD10−, activated memory as
CD19+CD27+CD21loCD10−, atypical memory CD19+
CD27−CD21loCD10− and immature transitional as
CD19+CD27−CD21loCD10+.
Statistical analysis
Statistical analysis and graphical presentation were done
using GraphPad Prism 6 (GraphPad, California, USA) and
STATA (StataCorp, Texas, USA). Mann-Whitney U test
was used for comparison between the study groups at each
visit. Results are presented as medians and interquartile
Longwe et al. BMC Immunology  (2015) 16:50 Page 2 of 7
Table 1 Comparison of the medians (Interquartile Range) of various cell type subsets at different time points
Cell Type or Ratio 6 Months 12 Months 18 Months
HEU HUU p HEU HUU p HEU HUU p
Total CD4+ T cells 55.20 (47.50 - 62.80) 58.40 (55.20 – 67.50) 0.04 54.80 (42.70 – 59.30) 51.10 (44.60 – 54.90) 0.62 54.80 (47.70 – 58.70) 48.80 (39.50 – 55.30) 0.05
Effector memory CD4+ T cells 6.8 (5.13 – 9.29) 6.47 (4.38 – 8.93) 0.53 9.7 (6.01 – 13.2) 7.64 (5.30 – 10.2) 0.19 11.9 (10.2 – 14.7) 12.1 (9.24 – 16.5) 0.89
CD4:CD8 Ratio 1.57 (1.16 – 2.18) 1.79 (1.47 – 2.54) 0.08 1.50 (1.00 – 1.90) 1.30 (1.05 – 1.78) 0.64 1.51 (1.10 – 1.92) 1.18 (0.80 - 1.63) 0.05
CD8+ T cells
Subsets
Total CD8+ T 35.10 (29.0 – 42.3) 32.60 (27.40 – 36.40) 0.15 36.40 (31.20 – 43.40) 39.30 (31.50 – 43.40) 0.63 36.70 (30.60 – 39.90) 41.70 (33.20 – 47.90) 0.05
Naïve 41.40 (27.6 – 51.3) 52.60 (36.50 – 67.50) 0.02 46.60 (33.50 – 56.80) 40.50 (33.40 – 64.20) 0.88 43.80 (36.00 – 53.30) 38.40 (26.70 – 48.50) 0.17
Central memory 1.94 (1.37 – 3.24) 2.11 (1.80 – 3.63) 0.38 1.48 (0.94 – 2.68) 1.48 (1.01 – 2.68) 0.82 1.17 (0.67 – 1.62) 1.08 (0.74 – 2.16) 0.75
Effector memory 19.50 (14.90 – 25.30) 14.30 (7.65 – 22.8) 0.04 14.10 (8.51 – 20.0) 13.70 (8.68 – 19.0) 0.89 11.20 (7.37 – 15.6) 14.10 (8.85 – 18.0) 0.28
Terminal Effector 32.50 (21.50 – 44.80) 27.40 (12.1 – 42.3) 0.15 37.40 (17.50 – 49.30) 37.20 (20.20 – 47.80) 0.96 41.60 (32.60 – 49.40) 44.70 (34.50 – 57.00) 0.29
B cells Subsets Total CD19+ B cells 23.30 (16.10 – 29.80) 20.7 (16.8 – 29.10) 0.91 20.70 (13.70 – 29.10) 20.90 (15.20 – 27.40) 0.98 20.10 (14.10 – 25.50) 18.80 (12.60 – 27.30) 0.91
Naïve 83.10 (79.20 – 85.60) 83.16 (80.70 – 87.90) 0.35 77.15 (71.20 – 78.90) 73.55 (70.60 – 81.90) 0.98 70.75 (66.40 – 77.20) 71.53 (63.20 – 74.00) 0.45
Immature/
Transitional
5.14 (2.14 – 7.11) 3.78 (2.21 – 5.09) 0.12 2.35 (1.39 – 4.19) 3.38 (1.70 – 4.54) 0.32 3.63 (2.26 – 6.98) 4.39 (2.41 – 5.47) 0.91
Classical Memory 5.98 (5.29 – 6.73) 5.26 (4.59 – 7.85) 0.58 12.11 (9.09 – 13.30) 12.27 (8.68 – 14.4) 0.92 12.72 (10.2 – 15.6) 13.05 (10.20 – 15.20) 0.95
Activated Memory 1.32 (0.77 – 2.41) 1.37 (0.85 – 2.16) 0.98 3.21 (2.12 – 3.85) 2.77 (1.64 – 3.78) 0.36 3.17 (2.42 – 4.53) 4.00 (3.17 – 5.22) 0.12
Atypical Memory 3.96 (2.65 – 6.17) 4.21 (2.75 – 5.65) 0.91 5.99 (2.86 – 7.78) 5.86 (3.84 – 7.77) 0.91 6.38 (4.28 – 9.34) 7.53 (4.28 – 11.6) 0.34
The p values presented in bold indicate statistically significant differences between the HEU and HUU values for each cell type
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Fig. 1 (See legend on next page.)
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ranges. Any differences between the study groups were
considered significant if p values were less than 0.05.
Results
Demographic details of the study participants have already
been reported previously [19]. At 6 months of age, the
median proportion of the total CD4+ T cells in HEU was
significantly lower compared to HUU children (55.2 vs.
58.4 %, p = 0.04) (Table 1). We did not find any significant
differences in the CD4 T cell subsets between the two
groups at all time points (Data not shown). Median propor-
tion of CD8+ T cells was similar between HEU children
compared to their HUU counterparts (35.1 vs. 32.6 %,
p = 0.15) (Fig. 1a). No differences were observed in the
median proportions of total CD4+ and CD8+ T cells be-
tween HEU and HUU children at 12 months: CD4+
(54.8 vs. 51.1 %, p = 0.621), CD8+ (36.4 vs. 39.3 %, p =
0.634) and 18 months:CD4+(54.8 vs. 48.8 %, p = 0.052),
CD8+ T cells (36.7 vs. 41.7 %, p = 0.056) (Table 1). HEU
children had significantly higher ratio of CD4:CD8
(p = 0.05) compared to HUU children (Table 1).
At 6 months, there was significantly lower proportion of
naïve CD8+T cells (41.4 vs. 52.6 %, p = 0.02) in HEU chil-
dren compared to HUU children (Fig. 1b). Interestingly, a
significantly high median proportion of TEM CD8
+T cells
(Fig. 1c) was observed in HEU children at 6 months com-
pared to HUU children (19.5 vs. 14.3 %, p = 0.04). No sig-
nificant differences were observed between HEU and
HUU children in median proportions of the remaining
CD8+ T subsets (Fig. 1b–e) at 12 and 18 months of age or
effector memory (TEM) CD4+ T cells (Table 1), either at 6,
12 or 18 months stages.
Median proportions of CD19+ B cells were similar
between HEU children compared to their HUU counter-
parts at 6 months (23.3 vs. 20.7 %, p = 0.91), 12 months
(20.7 vs. 20.9 %, p = 0.98) and 18 months (20.1 vs. 18.8 %,
p = 0.91). No significant differences were observed in the
median proportions of all B cell subsets (Fig. 1g–j), in
HEU children compared with HUU children at all three
time points.
Discussion
HEU children have been reported to present with immune
abnormalities during infancy, which are thought to be asso-
ciated with in utero exposure to HIV. We investigated how
B and T cell phenotypes from peripheral blood of HEU
children vary during and after CTX prophylaxis in
comparison with proportions in HUU children. We found
that the overall distribution of B and T cell phenotypes was
similar among HEU and HUU children at all time points
with some few exceptions. The proportion of total CD4+ T
cells was significantly lower in HEU children at 6 months
stage. HEU children had a lower proportion of naïve CD8+
T cells at six months which steadily increased with age. Of
much interest was the finding that HEU children had
higher proportion of effector memory CD8+ T cells com-
pared to HUU children at 6 months of age.
One study found that HEU Mozambican infants had
reduced percentage of CD4+ T cells at 1 month com-
pared to HUU children [20] and another study showed
that total CD4+ T cell counts were lower in HEU chil-
dren in early infancy compared to HUU children [21].
Exposure to maternally derived HIV proteins during
pregnancy has been suggested to be one possible cause
of the reduction in CD4+ T cell counts in HEU children
[21–23]. Our findings support the idea that HEU chil-
dren may have lower proportions of CD4+ T cells during
early infancy [24, 25], but this abnormality seems not to
last for longer than a year.
We also found that the proportions of naïve CD8+ T
cells were significantly reduced, whereas that of effector
memory CD8+ T cells was significantly higher, in HEU
children compared to HUU at 6 months of age. These
results support the hypothesis that there may be expos-
ure of the foetal immune system to HIV viral proteins in
utero and this may lead to immune activation that drives
CD8+ T cells into expansion and differentiation into
effector cells [26–28]. However, we expected the in vitro
exposure to have equally, if not in a more significantly
manner, affected the proportion of effector memory
CD4+ T cells too. The fact that we did not observe this
might be explained by the fact that these HIV-infected
mothers were on ART during their pregnancy and
during the time they were breastfeeding the HEU
children.
Alterations in the percentage of B lymphocytes in HIV
exposed neonates have been reported before [29] in a
study that showed B cells increased in cord blood of
HIV exposed neonates, supposedly caused by an increase
in CD19+CD5+ B cells. Higher CD19+ B cell percentages
among HEU infants (2 to 6 months) born to mothers
with high viral load (>1000 copies/ml) at the time of
delivery have also been reported [26]. The current study
showed no evidence of CD19+ B cell subset alteration in
(See figure on previous page.)
Fig. 1 Proportions of different subsets of CD8+ T cells and B cells in HEU and HUU children at different age: Figures a represents percentage of
CD8+T cells out of total lymphocytes, b naïve CD8+ T cells, c effector memory CD8+ T cells, d central memory CD8+ T cells and e terminal
effector CD8+ T cells. Figures f represents proportion of CD19+ B cells as a percentage of total lymphocytes, g naive B cells, h classical memory B
cell, i immature transitional B cells and j atypical memory B cells. Horizontal bars represent medians. Comparison between groups was performed
with Mann Whitney U test. A difference with a p value of less than 0.05 was considered to be statistically significant
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HEU children at 6, 12 and 18 months of age. This may
imply that the B cells ability to produce antibodies may
not be impaired in HEU children.
The study had a number of limitations. Firstly, no data
on lymphocyte subset proportions at birth for the chil-
dren were collected, as this would have provided an ideal
baseline for comparison with the subsequent follow-up
stages. Secondly, although all the HIV-infected mothers
were confirmed to be on ART, no data on CD4 T cell
counts or HIV viral load levels, or duration on ART
were collected from the mothers at the time of giving
birth and during the follow up period of the study.
Maternal disease status, especially their viral load at the
time of recruitment, might have affected the extent of
infant HIV exposure in utero and through breast milk
[26]. As such it is not easy for the study to ascertain
whether the lack of differences in the B and T cell phe-
notypes observed in the HEU group was due to reduced
exposure to HIV viral particles or not.
Having a control group comprising HEU children who
were not on CTX prophylaxis would have allowed us to
clearly specify if what was observed in the HEU on CTX
prophylaxis was indeed an effect of CTX on the propor-
tion of various cell subsets and not due to in utero HIV
exposure. However, ethically it was not possible to have
such a group since the current Malawi Government
guidelines clearly state that every HEU child should be
on CTX for the first year of life for the obvious benefi-
cial effects. We therefore used HUU recruited from
same communities as controls instead.
Conclusions
In conclusion, we have shown that there are no long
term alterations in the proportion of B and T cellsubsets
in HEU children compared to HUU children suggesting
that HEU children have a robust cellmediatedimmune
system during the first year of life.
Abbreviations
ART: Antiretroviral therapy; CTX: Cotrimoxazole; HEU: HIV-exposed but
uninfected; HUU: HIV-unexposed and uninfected; PMTCT: Prevention of
mother to child transmission.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: KSP, HL, WLM. Performed the
experiments: HL and KJ. Analyzed the data: HL KCJ WLM. Wrote the paper:
HL WLM, KCJ. Coordination and clinical work: NM and TG. All authors
amended the draft and approved the final manuscript.
Acknowledgements
We are grateful to all the parents and guardians for giving their consent and
the children for their cooperation. We are also grateful to Mr. Maurice
Mutisya and Dr. Simbarashe Takuva for offering statistical help. We thank the
whole study team in Zomba for collecting the data.
Funding
The study was funded by the Malawi Health Research Capacity
Strengthening Initiative (HRCSI), a DFID and Wellcome Trust funded
programme and the HIV Research Trust UK. This research was also partially
funded by Fellowship awards provided by the Consortium for Advanced
Research Training in Africa (CARTA) andSouthern Africa Consortium for
Research Excellence (SACORE). CARTA has been funded by the Wellcome
Trust (UK) (Grant No: 087547/Z/08/Z), the Department for International
Development (DfID) under the Development Partnerships in Higher Education
(DelPHE), the Carnegie Corporation of New York (Grant No: B 8606), the Ford
Foundation (Grant No: 1100-0399), Google.org (Grant No: 191994), Sida (Grant
No: 54100029) and the Bill and Melinda Gates Foundation (Grant No: 51228).
Author details
1Department of Basic Medical Sciences, College of Medicine, University of
Malawi, Blantyre, Malawi. 2Tropical Haematology Research Unit, College of
Medicine, University of Malawi, Blantyre, Malawi. 3Department of Public
Health, College of Medicine, University of Malawi, Blantyre, Malawi.
4Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre,
Malawi.
Received: 29 May 2015 Accepted: 25 August 2015
References
1. Study EC. Mother-to-child transmission of HIV infection in the era of highly
active antiretroviral therapy. Clin Infect Dis. 2005;40(3):458–65.
2. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones
SL. HIV-exposed uninfected children: a growing population with a vulnerable
immune system? Clin Exp Immunol. 2014;176(1):11–22.
3. Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, et al. HIV-exposed
uninfected infants are at increased risk for severe infections in the first year of
life. J Trop Pediatr. 2012;58(6):505–8.
4. Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child
mortality according to maternal and infant HIV status in Zimbabwe. Pediatr
Infect Dis J. 2007;26(6):519–26.
5. Janeway C. T cell mediated immunity. In: Murphy K, Travers P, Walport M,
editors. Janeway's Immunobiology. 7th ed. New York, US: Garland
Science; 2008.
6. Lewis M, Tarlton JF, Cose S. Memory versus naive T-cell migration. Immunol
Cell Biol. 2008;86(3):226–31.
7. Yamane H, Paul WE. Early signaling events that underlie fate decisions of
naive CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev.
2013;252(1):12–23.
8. Rohr JC, Gerlach C, Kok L, Schumacher TN. Single cell behavior in T cell
differentiation. Trends Immunol. 2014;35(4):170–7.
9. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory
T cell subsets: function, generation, and maintenance. Annu Rev Immunol.
2004;22:745–63.
10. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating
human B and plasma cells. Age-associated changes in counts and detailed
characterization of circulating normal CD138- and CD138+ plasma cells.
Haematologica. 2010;95(6):1016–20.
11. Mandala WL, MacLennan JM, Gondwe EN, Ward SA, Molyneux ME,
MacLennan CA. Lymphocyte subsets in healthy Malawians: implications for
immunologic assessment of HIV infection in Africa. J Allergy Clin Immunol.
2010;125(1):203–8.
12. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol.
2009;9(4):235–45.
13. Robillard N, Wuilleme S, Moreau P, Bene MC. Immunophenotype of normal
and myelomatous plasma-cell subsets. Front Immunol. 2014;5:137.
14. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, et al. Atypical
memory B cells are greatly expanded in individuals living in a
malaria-endemic area. J Immunol. 2009;183(3):2176–82.
15. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, et al. Evidence
for HIV-associated B cell exhaustion in a dysfunctional memory B cell
compartment in HIV-infected viremic individuals. J Exp Med.
2008;205(8):1797–805.
16. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early
chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected
Longwe et al. BMC Immunology  (2015) 16:50 Page 6 of 7
adults in Abidjan, cote d'Ivoire: a randomised trial. Cotrimo-CI study group.
Lancet. 1999;353(9163):1463–8.
17. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect
of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and
viral load in HIV infection in rural Uganda. Lancet. 2004;364(9443):1428–34.
18. Walker AS, Mulenga V, Ford D, Kabamba D, Sinyinza F, Kankasa C, et al. The
impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on
mortality and hospital admissions in HIV-infected Zambian children. Clin
Infect Dis. 2007;44(10):1361–7.
19. Longwe H, Jambo KC, Phiri KS, Mbeye N, Gondwe T, Hall T, et al. The
effect of daily co-trimoxazole prophylaxis on natural development of
antibody-mediated immunity against P. falciparum malaria infection in
HIV-exposed uninfected Malawian children. PLoS One. 2015;10(3):e0121643.
20. Moraleda C, de Deus N, Serna-Bolea C, Renom M, Quinto L, Macete E, et al.
Impact of HIV exposure on health outcomes in HIV-negative infants born to
HIV-positive mothers in Sub-Saharan Africa. J Acquir Immune Defic Syndr.
2014;65(2):182–9.
21. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D, et al.
T-lymphocyte maturation abnormalities in uninfected newborns and
children with vertical exposure to HIV. Blood. 2000;96(12):3866–71.
22. Ono E, Santos AM N d, de Menezes Succi RC, Machado DM, de Angelis DS,
Salomao R, et al. Imbalance of naive and memory T lymphocytes with
sustained high cellular activation during the first year of life from uninfected
children born to HIV-1-infected mothers on HAART. Braz J Med Biol Res.
2008;41(8):700–8.
23. Nielsen SD, Jeppesen DL, Kolte L, Clark DR, Sorensen TU, Dreves AM, et al.
Impaired progenitor cell function in HIV-negative infants of HIV-positive
mothers results in decreased thymic output and low CD4 counts. Blood.
2001;98(2):398–404.
24. Bunders M, Thorne C, Newell ML. Maternal and infant factors and
lymphocyte, CD4 and CD8 cell counts in uninfected children of
HIV-1-infected mothers. AIDS. 2005;19(10):1071–9.
25. Gesner M, Papaevangelou V, Kim M, Chen SH, Moore T, Krasinski K, et al.
Alteration in the proportion of CD4 T lymphocytes in a subgroup of human
immunodeficiency virus-exposed-uninfected children. Pediatrics.
1994;93(4):624–30.
26. Kakkar F, Lamarre V, Ducruet T, Boucher M, Valois S, Soudeyns H, et al.
Impact of maternal HIV-1 viremia on lymphocyte subsets among
HIV-exposed uninfected infants: protective mechanism or
immunodeficiency. BMC Infect Dis. 2014;14(1):236.
27. Kidzeru EB, Hesseling AC, Passmore JA, Myer L, Gamieldien H, Tchakoute CT,
et al. In-utero exposure to maternal HIV infection alters T-cell immune
responses to vaccination in HIV-uninfected infants. AIDS.
2014;28(10):1421–30.
28. Kuhn L, Coutsoudis A, Moodley D, Trabattoni D, Mngqundaniso N, Shearer
GM, et al. T-helper cell responses to HIV envelope peptides in cord blood:
protection against intrapartum and breast-feeding transmission. AIDS.
2001;15(1):1–9.
29. Borges-Almeida E, Milanez HM, Vilela MM, Cunha FG, Abramczuk BM,
Reis-Alves SC, et al. The impact of maternal HIV infection on cord blood
lymphocyte subsets and cytokine profile in exposed non-infected
newborns. BMC Infect Dis. 2011;11:38.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Longwe et al. BMC Immunology  (2015) 16:50 Page 7 of 7
